- For Print
- April 24, 2024
ÎÚÑ»´«Ã½. (Headquarters: Tokyo, CEO: Haruo Naito, “ÎÚÑ»´«Ã½”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). ÎÚÑ»´«Ã½’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in ÎÚÑ»´«Ã½'s financial disclosure scheduled on May 15, 2024.
ÎÚÑ»´«Ã½ serves as the lead of lecanemab development and regulatory submissions globally with both ÎÚÑ»´«Ã½ and Biogen Inc. co-commercializing and co-promoting the product and ÎÚÑ»´«Ã½ having final decision-making authority.
&²Ô²ú²õ±è;〶Ä
&²Ô²ú²õ±è;〶Ä
Media Inquiries:
Public Relations Department,
ÎÚÑ»´«Ã½.
+81-(0)3-3817-5120
&²Ô²ú²õ±è;〶Ä